Search results
Results From The WOW.Com Content Network
A number of companies were expected to develop Ebola vaccines: GlaxoSmithKline, NewLink Genetics, Johnson & Johnson, and Bavarian Nordic. [82] Another company, Emergent BioSolutions, was a contestant for manufacturing new doses of ZMapp, [citation needed] a drug for Ebola virus disease treatment originally developed by Mapp Biopharmaceutical. [83]
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
During the 2018 Équateur province Ebola outbreak, a similar monoclonal antibody treatment, mAb114, was requested by the Democratic Republic of Congo (DRC) Ministry of Public Health. mAb114 was approved for compassionate use by the World Health Organization MEURI ethical protocol and at DRC ethics board. mAb114 was sent along with other ...
The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...
A stockpile of half-a-million Ebola vaccine doses was established by Gavi and other global health partners in 2019 for use in outbreaks of haemorrhagic fever, which has an average fatality rate of ...
cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID). [1]
Flu vaccines used during the flu in 2009. This is a list of vaccine-related topics.. A vaccine is a biological preparation that improves immunity to a particular disease.A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe or its toxins.
Scientists have used pseudo types that have the same glycoprotein on the surface that is used for entry into the host cell. They also use noninfectious Ebola-like particles as a replacement system to study. [29] The search for a vaccine for Ebola began immediately after it was first discovered in 1976. [30]